Table 5.

The prevalence of MetS by age group with four definitions, the prevalence ratios (PR) and 95% CIs for age groups

Male
	WHO			NCEP-ATP III			IDF			JIS
Age groups	%	PR	95% CI	%	PR	95% CI	%	PR	95% CI	%	PR	95% CI
25-34	4.0	1.0		14.5	1.0		16.9	1.0		19.3	1.0
35-44	7.1	1.8	1.0-3.2	24.0	1.7	1.2-2.2	30.9	1.8	1.4-2.4	33.5	1.7	1.4-2.2
45-54	21.2	5.3	3.1-9.0	38.9	2.7	2.1-3.5	48.9	2.9	2.3-3.7	51.9	2.7	2.2-3.4
55-64	30.0	7.5	4.5-12.5	44.1	3.0	2.4-4.0	55.9	3.3	2.6-4.2	58.1	3.0	2.4-3.8
65-74	36.2	9.1	5.4-15.1	47.4	3.3	2.5-4.3	60.3	3.6	2.8-4.5	61.7	3.2	2.6-4.0
75+	31.8	8.0	4.7-13.5	33.1	2.3	1.7-3.1	52.1	3.1	2.4-4.0	56.8	2.9	2.3-3.7
Female
	WHO			NCEP-ATP III			IDF			JIS
Age groups	%	PR	95% CI	%	PR	95% CI	%	PR	95% CI	%	PR	95% CI
25-34	0.9	1.0		5.8	1.0		6.7	1.0		7.1	1.0
35-44	2.6	2.9	1.0-8.8	13.0	2.2	1.5-3.5	17.8	2.7	1.8-4.0	17.8	2.5	1.7-3.7
45-54	8.8	9.8	3.6-26.9	27.5	4.7	3.3-7.3	32.4	4.8	3.4-7.2	32.8	4.6	3.3-6.7
55-64	14.4	16.0	5.9-43.2	38.7	6.7	4.6-10.2	45.2	6.8	4.8-9.9	46.2	6.5	4.7-9.4
65-74	23.4	26.0	9.7-69.6	47.6	8.2	5.7-12.5	57.7	8.6	6.2-12.6	59.0	8.3	6.0-11.9
75+	33.3	37.0	13.8-99.2	54.7	9.4	6.6-14.4	65.6	9.8	7.0-14.4	66.9	9.4	6.8-13.6

PR=prevalence ratio